These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20008852)

  • 1. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
    Milojkovic D; Apperley J
    Clin Cancer Res; 2009 Dec; 15(24):7519-7527. PubMed ID: 20008852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
    Cang S; Liu D
    J Hematol Oncol; 2008 Oct; 1():15. PubMed ID: 18828913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
    Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia].
    Almeida A; Castro I; Coutinho J; Guerra L; Marques H; Pereira AM
    Acta Med Port; 2009; 22(5):537-44. PubMed ID: 19944036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
    Irvine DA; Heaney NB; Holyoake TL
    Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
    Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
    Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging treatment options in chronic myeloid leukemia.
    Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
    Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.
    Alves R; Gonçalves AC; Rutella S; Almeida AM; De Las Rivas J; Trougakos IP; Sarmento Ribeiro AB
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs.
    Amir M; Javed S
    Front Genet; 2021; 12():742802. PubMed ID: 34745216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late Emergence of an Imatinib-Resistant
    Crampe M; Andrews C; Fortune A; Langabeer SE
    Case Rep Hematol; 2017; 2017():3548936. PubMed ID: 29375916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Plasticity Is an Essential Requirement of Acquired Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
    Mostazo MGC; Kurrle N; Casado M; Fuhrmann D; Alshamleh I; Häupl B; Martín-Sanz P; Brüne B; Serve H; Schwalbe H; Schnütgen F; Marin S; Cascante M
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33228196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming imatinib resistance conferred by the
    Liu J; Bhadra M; Sinnakannu JR; Yue WL; Tan CW; Rigo F; Ong ST; Roca X
    Oncotarget; 2017 Sep; 8(44):77567-77585. PubMed ID: 29100409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.